Want to see HK:6681 full AI Analyst Report?
BrainAurora Medical Technology Limited (6681) AI Stock Analysis
BrainAurora Medical Technology Limited
(HKEX:6681)
The score is held back primarily by weak financial performance—large losses, high leverage, and persistent cash burn—despite strong revenue growth and decent gross margin. Technicals are supportive with positive momentum and the price above major moving averages, but valuation remains pressured by negative earnings and no stated dividend yield.
BrainAurora Medical Technology Limited (6681) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 2.21B
- Dividend Yield
- ―
- Average Volume (3M)
- 72.79M
- Price to Earnings (P/E)
- -5.3
- Beta (1Y)
- 1.00
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 165
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
BrainAurora Medical Technology Limited Business Overview & Revenue Model
Company Description
BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evalua...
BrainAurora Medical Technology Limited Financial Statement Overview
Summary
Despite very strong revenue growth and a healthy gross margin (~41% in 2025), financial quality is weak due to deep losses (net margin ~-143%), high and rising leverage (debt-to-equity ~5.8x), and ongoing cash burn (2025 operating cash flow ~-178M; free cash flow ~-206M). Equity turning positive and narrowing losses are positives but not enough to offset the risk profile.
Income Statement
22NegativeBalance Sheet
14Very NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 239.86M | 220.05M | 122.31M | 67.20M | 11.29M | 2.30M |
| Gross Profit | 103.21M | 89.45M | 54.01M | 32.06M | 3.30M | 1.30M |
| EBITDA | -256.54M | -264.78M | -149.39M | -317.63M | -470.81M | -689.82M |
| Net Income | -322.47M | -314.86M | -198.28M | -359.08M | -502.45M | -697.84M |
Balance Sheet | ||||||
| Total Assets | 1.05B | 733.20M | 599.50M | 394.85M | 418.09M | 371.30M |
| Cash, Cash Equivalents and Short-Term Investments | 658.44M | 531.78M | 343.88M | 57.58M | 287.22M | 323.74M |
| Total Debt | 556.24M | 565.76M | 388.28M | 364.07M | 328.14M | 308.76M |
| Total Liabilities | 629.79M | 637.69M | 1.06B | 727.03M | 1.51B | 1.05B |
| Stockholders Equity | 419.32M | 97.39M | -463.65M | -332.14M | -1.09B | -681.28M |
Cash Flow | ||||||
| Free Cash Flow | -74.67M | -205.75M | -167.24M | -155.00M | -119.74M | -60.31M |
| Operating Cash Flow | -67.88M | -178.03M | -149.49M | -136.87M | -100.68M | -49.21M |
| Investing Cash Flow | -105.33M | -272.88M | 125.37M | 102.55M | -334.46M | -21.48M |
| Financing Cash Flow | 116.19M | 339.27M | 315.50M | 63.53M | 139.65M | 393.61M |
BrainAurora Medical Technology Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6681, the sentiment is Positive. The current price of 1.63 is above the 20-day moving average (MA) of 1.01, above the 50-day MA of 1.22, and below the 200-day MA of 2.92, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 65.38 is Neutral, neither overbought nor oversold. The STOCH value of 69.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6681.
BrainAurora Medical Technology Limited Peers Comparison
Overall Rating
HK:152163Neutral
HK:334755Neutral
HK:662255Neutral
HK:215753Neutral- HK:668150Neutral
HK:147743Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1521 | 63Neutral | HKD 3.04B | 36.53 | 3.02% | ― | 10.32% | 178.23% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:3347 | 55Neutral | HKD 42.54B | -76.42 | -2.00% | 0.38% | 21.72% | -169.67% |
| HK:6622 | 55Neutral | HKD 1.11B | -4.50 | -14.41% | ― | 2.56% | 20.20% |
| HK:2157 | 53Neutral | HKD 5.69B | 19.79 | 17.36% | ― | 46.90% | ― |
| HK:6681 | 50Neutral | HKD 2.21B | -5.32 | -124.83% | ― | ― | ― |
| HK:1477 | 43Neutral | HKD 3.91B | -26.50 | -3.44% | ― | 77.55% | 50.34% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6681 | BrainAurora Medical Technology Limited | 1.63 | -5.92 | -78.41% | |
| HK:3347 | Hangzhou Tigermed Consulting Co., Ltd. Class H | 37.92 | -8.52 | -18.35% | |
| HK:1477 | Ocumension Therapeutics | 4.79 | -3.67 | -43.38% | |
| HK:1521 | Frontage Holdings Corp. | 1.49 | 0.32 | 27.35% | |
| HK:2157 | Lepu Biopharma Co. Ltd. Class H | 3.15 | -3.23 | -50.55% | |
| HK:6622 | Zhaoke Ophthalmology Ltd. | 2.02 | -1.13 | -36.03% |
BrainAurora Medical Technology Limited Corporate Events
BrainAurora Wins First Beijing Approval for Depression Cognitive Assessment Device
BrainAurora Medical Technology has received a Class II Medical Device Registration Certificate from the Beijing Municipal Medical Products Administration for its standalone cognitive function assessment software for patients with depression. The prod...
BrainAurora defines optimal pediatric doses for cognitive digital therapeutics in major BMC Medicine study
BrainAurora Medical Technology has reported the publication of a major study in BMC Medicine that defines optimal digital training doses for children and adolescents with cognitive impairments using its Brain Function Information Management Platform....
BrainAurora’s Self-Adaptive Digital Therapy Shows Strong Schizophrenia Results
BrainAurora Medical Technology Limited has reported new clinical research results demonstrating the efficacy of its self-adaptive computerized cognitive remediation technology for schizophrenia. The study used the company’s Brain Function Infor...
BrainAurora lifts revenue as it deepens push into AI cognitive digital therapeutics
BrainAurora Medical Technology Limited reported interim revenue of RMB119.9 million for the six months ended June 30, 2026, up 19.8% year on year, while its loss widened modestly, with total comprehensive expense at RMB134.6 million and an adjusted n...
BrainAurora Schedules Board Meeting to Approve Interim 2026 Results
BrainAurora Medical Technology Limited, a listed medical technology company incorporated in the Cayman Islands and traded on the Hong Kong Stock Exchange, operates through a group structure focused on healthcare innovation and related services. Its g...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026